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The present study investigates the effect of compounds that are known to elevate CAMP on the phospholipid 
metabolism of platelets. Prostaglandin E,, forskolin and isobutylmethylxanthine induce an increase in [“PI- 
phosphatidylinositol Cphosphate (PIP) in platelets prelabelled with [32P]orthophosphate. Possible roles of 
this phenomenon are discussed in view of the inhibitory effect of CAMP elevation on platelet activation. 
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1. INTRODUCTION 
Inositol phospholipids are involved in the signal 
transducing system of many platelet stimuli 
(review [ 1,2]). Phosphatidylinositol 4,5bisphos- 
phate (PIP2) is apparently of major importance. 
Its phosphodiesteratic leavage yields diacylglyc- 
erol and inositol trisphosphate. Diacylglycerol ac- 
tivates the C kinase which plays an important role 
in the physiological response [2]. Inositol trisphos- 
phate has been demonstrated to be a potential 
mediator of Ca’+ release from intracellular Ca 
stores [l]. 
Phosphatidylinositol4-phosphate (PIP) is an in- 
termediate between phosphatidylinositol (PI) and 
PIP2. In [3,4] we showed that direct activation of 
C kinase by 1 -oleoyl-2-acetylglycerol (OAG) and 
12-0-tetradecanoyl phorbol 13-acetate (TPA) 
stimulates 32P incorporation predominantly in 
PIP. Authors in [5] demonstrated that the increase 
in incorporation corresponded to an increase in 
mass. 
More recently the direct activation of C kinase 
was reported to have a negative feedback control 
over agonist-induced hydrolysis of inositol 
phospholipids. Treatment of cellular systems with 
OAG or TPA inhibited the effects of agonists on 
the primary receptor-coupled biochemical events 
as there are the activation of phospholipase C 
[7-111 and the increase in intracellular free Ca2+ 
[7-9,11,12]. 
Inhibition of the same events occurs when 
platelets are treated with agents known to elevate 
their CAMP content [13-201. 
In analogy with our findings on OAG and TPA- 
induced PIP formation, we investigated whether 
agents known to elevate platelet CAMP also in- 
crease [32P]PIP formation. 
2. MATERIALS AND METHODS 
Prostaglandin El (PGEi) and phospholipid 
reference product were obtained from Sigma (St. 
Louis, USA). IBMX (isobutylmethylxanthine) was 
from Janssen Chimica (Beerse) and forskolin (FK) 
from Calbiochem (La Jolla, USA). Silica gel 
60-precoated plastic sheets were from E. Merck, 
FRG. [32P]Orthophosphate was obtained from 
Amersham (England). Proteins for Mr determina- 
tions on SDS-polyacrylamide gels were from Bio- 
Rad. Platelet preparation, “P labelling of 
platelets, and lipid and protein analyses were per- 
formed exactly as in [21]. 
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The control 32P incorporation was always deter- 
mined in the presence of the solvent for the com- 
pounds tested (1960 ethanol for PGEz and FK, 1% 
DMSG for IBMX). Pre~min~y experiments had 
shown that the solvents alone had no influence on 
32P incorporation. Within the different ex- 
periments the control labelling in the PIP pool 
varied between 35000 and 100000 cpm. Within the 
time course of an experiment he incorporation did 
not significantly change 1211. The changes with ad- 
dition of a compound are expressed as 070 of the 
control 32P incorporation. 
3. RESULTS 
On addition of PGEi (low6 M), FK (10T5 M) 
and IBMX (10m3 M) the 32P incorporation in PIP 
increased (fig.1). None of the compounds 
significantly altered 32P incorporation in the other 
lipid fractions (PIP2, PI, phosphatidic 
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Fig.1. Changes in [32P]PIP after addition of PGEi, FK 
or IBMX. POE1 (10e6 M) (o---o), FK (10v5 M) 
(o--O) and IBMX (10e3 M) (M) were added to 
platelets prelabelled with [32P]orthophosphate. At the 
indicated times, platelet samples were taken and 
incubation was stopped by adding the platelets to 
organic solvent (see section 2). Points represent the 
means + SE of duplicate samples from 4 (for PGEI and 
FK) and 2 (for IBMX) experiments. The control 32P 
incorporation was taken as 100% for each experiment 
(see section 2). 
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acid, phosphatidylcholine and lysophosphatidyl- 
inositol) (not shown). The onset of phosphoryla- 
tion differed for the 3 compounds. Phosphorylation 
induced by PGEt is more rapid than that of FK 
(fig. 1); after 30 s the former reached about 70% of 
its maximum whereas the latter attained only 
30-3970. [32P]PIP formation induced by IBMX is 
low and more delayed (fig.l), being half maximal 
only after about 1 min. 
Fig.2 illustrates that the changes in PIP induced 
by PGEl and FK are clearly concentration- 
dependent, PGEl being the most potent com- 
pound. The changes in [32P]PIP provoked by 
IBMX were too small to assess accurately a dose 
dependency. 
PGEi , FK and IBMX induce phosphorylation of 
a 50 kDa, a 27 kDa and a 24 kDa protein (not 
shown) most probably by the activation of a 
CAMP-dependent protein kinase. Similar changes 
in protein phosphorylation patterns were found by 
others 122-24). The 40 kDa protein phosphoryla- 
tion (substrate for C kinase) was not affected [25]. 
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Fig.2. Concentration-dependent changes in [32P]PIP. 
PGEi and FK were added to platelets prelabelled with 
[32P]orthophosphate. After 25 s (for PGEr) and 1 mm 
(for FK) the incubation was stopped as described in the 
legend to fig.1. Points represent the means * SE of 
duplicate samples from 4 (for PGEi) and 3 (for FK) 
experiments. The control 32P incorporation was taken as 
100% for each experiment. 
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4. DISCUSSION 
Platelets have a bidirectional control system for 
transduction of an extracellular signal to the cell 
interior. Platelet activation by excitatory stimuli, 
that use Ca” and diacylglycerol as messengers, is
antagonized by inhibitory platelet stimuli known 
to provoke a rise in CAMP [13-201 such as 
prostaglandins (i.e. PGEi, PGDz, PGIz), FK and 
IBMX. Although acting through a different 
mechanism to elevate CAMP, the latter compounds 
all induce an increase in the [32P]PIP levels in the 
platelet. 
The complex metabolism of the polyphospho- 
inositides does not allow one to assign unequivo- 
cally this alteration to a specific enzymatic step. In- 
creased [32P]PIP formation can be explained 
through phosphorylation of PI as we discussed in 
[4]. This statement is in agreement with findings 
that the CAMP-dependent protein kinase 
stimulates the formation of polyphosphoinositides 
in plasma membranes from platelets [26] and the 
formation of PIP in plasma membranes from pig 
granulocytes [27]. Since an elevation of platelet 
PIP levels in a resting platelet does not appear 
physiologically relevant it is tempting to look for a 
separate role for PIP besides being an intermediate 
metabolite between PI and PIPz. In this context 
the finding of authors in [28,29] that PIP might be 
involved in Ca transport ATPases is attractive. 
Both activation of the C kinase [9] and addition of 
PGEr [20] have been shown to stimulate Ca2+ ex- 
trusion from the platelet cytoplasm. This lowering 
of a steady-state level of Ca2+ (second or third 
messenger) might evidently contribute to the in- 
hibitory effects seen in these conditions. 
Alternatively, a CAMP-induced shift of the PIP 
e PIP2 equilibrium to the left can explain an ac- 
cumulation of [32P]PIP. Since the inositol lipid cy- 
cle [PIP2 - DAG (+ Ip3) - PA -PI - 
PIP - PIP21 does occur in the resting platelet 
[19,30], this would lead to concomitant lower 
steady-state levels of metabolites distal to PIP in 
inositol lipid cycle. Of major importance in the in- 
hibitory effect of agents that elevate platelet CAMP 
would be the lowering in PIP2 as substrate for 
agonist-induced phospholipase C and the decrease 
in steady-state levels of the putative second 
messengers (Ip3 and DAG). Small changes in the 
equilibrium PIP + PIP2 would have an 
amplificatory inhibitory effect on platelet activa- 
tion; also, the excitatory agonist-induced increase 
as the basal levels of the second messenger would 
be lowered. 
In conclusion, we found that agents known to 
elevate platelet CAMP induce an increase in 
[32P]PIP in the human platelet. Complete analogy 
at the level of signal transduction is now found be- 
tween the negative feedback control of platelet ac- 
tivation by the C kinase and the inhibitory effect of 
agents that elevate platelet CAMP since both 
phenomena coincide with (i) a decrease in cytosolic 
Ca’+, (ii) a decrease in phospholipase C activity 
and (iii) an increase in PIP formation. A possible 
role for the latter remains to be elucidated. 
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